Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0YKHCA
ADC Name	AbGn-107
Synonyms	AbGn 107; AbGn107 Click to Show/Hide
Organization	AbGenomics International, Inc.
Drug Status	Phase 1
Indication	In total 4 Indication(s) Biliary tract cancer [ICD11:2C15] Phase 1 Colorectal cancer [ICD11:2B91] Phase 1 Gastric cancer [ICD11:2B72] Phase 1 Pancreatic cancer [ICD11:2C10] Phase 1
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	AG7		Antigen Info
Payload Name	Undisclosed
Linker Name	Undisclosed
Puchem SID	404720095
TTD ID	D08GZE
ChEBI ID	CHEMBL4297683

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT02908451	Phase 1	A phase 1 dose escalation study, with cohort expansion, to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABGN-107 therapy in patients with chemo-refractory locally advanced, recurrent, or metastatic gastric, colorectal, pancreatic or biliary cancer. Click to Show/Hide

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	11.40% (all)
Patients Enrolled	Patients with locally advanced or metastatic G, CRC, PDA, or BIL cancer, previously treated, ECOG PS 0-1, positive AG-7 expression was not required.
Administration Dosage	AbGn-107 administered iv Q4 weeks (from 0.10-1.20 mg/kg) and Q2 weeks (from 0.80-1.00 mg/kg).
*Related Clinical Trial*
NCT Number	NCT02908451	Clinical Status	Phase 1
Clinical Description	A phase 1 dose escalation study, with cohort expansion, to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABGN-107 therapy in patients with chemo-refractory locally advanced, recurrent, or metastatic gastric, colorectal, pancreatic or biliary cancer.

References

Ref 1	A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors. J Clin Oncol. 2023 41:16_suppl, 3029-3029.